YM
Therapeutic Areas
Innate Pharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Lacutamab (IPH4102) | Cutaneous T-cell Lymphoma (CTCL), Sézary Syndrome | Phase 3-ready |
| IPH4502 | Solid Tumors (Nectin-4 target) | Phase 1 |
| Monalizumab (IPH2201) | Non-Small Cell Lung Cancer (NSCLC) | Phase 3 |
| IPH6501 | Not specified | Phase 1/2 |
| IPH6101 / SAR'579 | Not specified (ANKET® program) | Phase 1/2 |
| IPH6401 / SAR'514 | Not specified (ANKET® program) | Phase 1/2 |
| IPH5201 | Not specified (CD39 target) | Phase 1 |
| IPH5301 | Not specified (CD73 target) | Pre-clinical/Phase 1 |
Leadership Team at Innate Pharma
JD
Jonathan DICKINSON
Chief Executive Officer
SQ
Sonia QUARATINO
Executive Vice President, Chief Medical Officer
NB
Nicola BELTRAMINELLI
Vice President, Chief Development Officer
OB
Odile BELZUNCE
Vice President Compliance & Operations
SC
Stéphanie CORNEN
Vice President, Investor Relations, Communication & Commercial Strategy
CD
Claire de SAINT BLANQUAT
Vice President, Legal and Corporate Affairs and Secretary of the Supervisory Board
OL
Odile LAURENT
Vice President, Human Resources and Social Relations
FL
Frédéric LOMBARD
Senior Vice President, Chief Financial Officer
IS
Irina STAATZ-GRANZER
Chairwoman of the Board of Directors
PB
Pascale BOISSEL
Vice Chairperson of the Board of Directors